MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 12:13:49 2024-07-11 pm EDT | ||
| 13.24 EUR | -3.04% |
|
| Current month | -8.28% | ||
| 1 month | -5.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 13.24 | -3.04% |
| 24-07-10 | 13.66 | +1.52% |
| 24-07-09 | 13.45 | -3.41% |
| 24-07-08 | 13.92 | +1.98% |
| 24-07-05 | 13.66 | +1.45% |
Real-time Euronext Paris
Last update July 11, 2024 at 12:13 pm EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| AR9KB | |
| ISIN | FRBNPP05LJ03 |
| Date issued | 2023-04-17 |
| Strike | 471.1 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.66 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.13 € |
|---|---|
| Lowest since issue | 1.685 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.11%
- Stock Market
- Certificates
- AR9KB Certificat
